Legal Representation
Attorney
Devon E. White
USPTO Deadlines
Next Deadline
56 days remaining
Non-Final Action E-Mailed
Due Date
February 18, 2026
Extension Available
Until May 18, 2026
Application History
7 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 18, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Nov 18, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Nov 18, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Nov 18, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 4, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 30, 2025 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Jun 30, 2025 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
Chemical preparations for scientific purposes; Molecules for use in industry, namely, protein-modulating molecules for use in the pharmaceutical industry; Molecules for use in science, namely, protein-modulating molecules for use in the pharmaceutical industry; Molecules for molecular biology, other than for medical or veterinary use, namely, protein-modulating molecules for use in the pharmaceutical industry
Class 005
Pharmaceutical and therapeutic preparations, namely, a drug formulation using protein degradation for use in treating immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Biochemical preparations for medical use for the treatment of immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Pharmaceutical preparations for targeted protein degradation, comprising small molecules, peptides, biologics, antibodies designed for the treatment of immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Proteins, protein fragments, and protein conjugates all for use in the manufacture of pharmaceutical preparations for treatment of immunologic diseases, particularly autoimmune diseases
Classification
International Classes
001
005